LQDA Stock Forecast & Price Target

Liquidia Corp has revised its sales estimates for YUTREPIA upwards to a peak of $1.7 billion to $2 billion, reflecting a stronger-than-expected launch and uptake in the pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) markets. The company's positive trajectory is further supported by achieving operating profitability in the first full quarter following YUTREPIA's launch, alongside improved metrics such as an 85% patient conversion rate. Additionally, Liquidia's strategic partnerships with the three largest payors and the successful integration of therapeutic options like sotatercept may enhance patient accessibility and further drive product adoption.

Liquidia Corp faces substantial legal risks that threaten the exclusivity of its primary revenue source, YUTREPIA, which could significantly undermine its top-line growth potential. The ongoing litigation concerning UTHR's patents poses a significant downside risk if Liquidia does not prevail, as unfavorable outcomes could disrupt sales continuity and result in considerable financial penalties. Furthermore, the variations in patent expiration dates highlight the ongoing uncertainty surrounding YUTREPIA's long-term operational viability.